Ferring Pharma Signs Deal With Apricus To Commercialize Vitaros - Quick Facts

(RTTNews) - Apricus Biosciences, Inc. (APRI) announced it has signed an exclusive distribution agreement with Ferring Pharmaceuticals to market Vitaros (alprostadil), its topical on-demand product for the treatment of erectile dysfunction, in Latin American countries.

Apricus will receive $2.25 million from Ferring in an upfront payment. Apricus is also eligible to receive up to $16 million in regulatory and sales milestone payments, in addition to royalties based on Ferring's net sales of the product in the territory.

Vitaros is a topical ED cream that delivers rapid onset (generally 5-15 minutes), and treatment duration of approximately one hour.